Serveur d'exploration sur l'automédication dans le monde francophone

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.

Identifieur interne : 000015 ( Main/Exploration ); précédent : 000014; suivant : 000016

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.

Auteurs : Caroline Bascoul-Mollevi [France] ; Antoine Barbieri [France] ; Céline Bourgier [France] ; Thierry Conroy [France] ; Bruno Chauffert [France] ; Mohamed Hebbar [France] ; William Jacot [France] ; Beata Juzyna [France] ; Hélène De Forges [France] ; Sophie Gourgou [France] ; Franck Bonnetain [France] ; Célia Touraine [France] ; Amélie Anota [France]

Source :

RBID : pubmed:32809099

Descripteurs français

English descriptors

Abstract

PURPOSE

Health-related quality of life (HRQoL) is assessed by self-administered questionnaires throughout the care process. Classically, two longitudinal statistical approaches were mainly used to study HRQoL: linear mixed models (LMM) or time-to-event models for time to deterioration/time until definitive deterioration (TTD/TUDD). Recently, an alternative strategy based on generalized linear mixed models for categorical data has also been proposed: the longitudinal partial credit model (LPCM). The objective of this article is to evaluate these methods and to propose recommendations to standardize longitudinal analysis of HRQoL data in cancer clinical trials.

METHODS

The three methods are first described and compared through statistical, methodological, and practical arguments, then applied on real HRQoL data from clinical cancer trials or published prospective databases. In total, seven French studies from a collaborating group were selected with longitudinal collection of QLQ-C30. Longitudinal analyses were performed with the three approaches using SAS, Stata and R software.

RESULTS

We observed concordant results between LMM and LPCM. However, discordant results were observed when we considered the TTD/TUDD approach compared to the two previous methods. According to methodological and practical arguments discussed, the approaches seem to provide additional information and complementary interpretations. LMM and LPCM are the most powerful methods on simulated data, while the TTD/TUDD approach gives more clinically understandable results. Finally, for single-item scales, LPCM is more appropriate.

CONCLUSION

These results pledge for the recommendation to use of both the LMM and TTD/TUDD longitudinal methods, except for single-item scales, establishing them as the consensual methods for publications reporting HRQoL.


DOI: 10.1007/s11136-020-02605-3
PubMed: 32809099


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.</title>
<author>
<name sortKey="Bascoul Mollevi, Caroline" sort="Bascoul Mollevi, Caroline" uniqKey="Bascoul Mollevi C" first="Caroline" last="Bascoul-Mollevi">Caroline Bascoul-Mollevi</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Barbieri, Antoine" sort="Barbieri, Antoine" uniqKey="Barbieri A" first="Antoine" last="Barbieri">Antoine Barbieri</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm UMR 1219, University Bordeaux, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm UMR 1219, University Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Bourgier, Celine" sort="Bourgier, Celine" uniqKey="Bourgier C" first="Céline" last="Bourgier">Céline Bourgier</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Radiation Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Radiation Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Conroy, Thierry" sort="Conroy, Thierry" uniqKey="Conroy T" first="Thierry" last="Conroy">Thierry Conroy</name>
<affiliation wicri:level="3">
<nlm:affiliation>Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
<settlement type="city">Vandœuvre-lès-Nancy</settlement>
<settlement type="city" wicri:auto="agglo">Nancy</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Lorraine University, APEMAC, Team MICS, Nancy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Lorraine University, APEMAC, Team MICS, Nancy</wicri:regionArea>
<placeName>
<region type="region">Grand Est</region>
<region type="old region">Lorraine (région)</region>
<settlement type="city">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Chauffert, Bruno" sort="Chauffert, Bruno" uniqKey="Chauffert B" first="Bruno" last="Chauffert">Bruno Chauffert</name>
<affiliation wicri:level="3">
<nlm:affiliation>Medical Oncology Department, Amiens University Hospital, Amiens, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Medical Oncology Department, Amiens University Hospital, Amiens</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Picardie</region>
<settlement type="city">Amiens</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hebbar, Mohamed" sort="Hebbar, Mohamed" uniqKey="Hebbar M" first="Mohamed" last="Hebbar">Mohamed Hebbar</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Medical Oncology, University Hospital, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, University Hospital, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Jacot, William" sort="Jacot, William" uniqKey="Jacot W" first="William" last="Jacot">William Jacot</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Medical Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Juzyna, Beata" sort="Juzyna, Beata" uniqKey="Juzyna B" first="Beata" last="Juzyna">Beata Juzyna</name>
<affiliation wicri:level="3">
<nlm:affiliation>R&D Unicancer, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>R&D Unicancer, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="De Forges, Helene" sort="De Forges, Helene" uniqKey="De Forges H" first="Hélène" last="De Forges">Hélène De Forges</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinical Research and Innovation Department, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Research and Innovation Department, Institut du Cancer Montpellier, University Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gourgou, Sophie" sort="Gourgou, Sophie" uniqKey="Gourgou S" first="Sophie" last="Gourgou">Sophie Gourgou</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Bonnetain, Franck" sort="Bonnetain, Franck" uniqKey="Bonnetain F" first="Franck" last="Bonnetain">Franck Bonnetain</name>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Touraine, Celia" sort="Touraine, Celia" uniqKey="Touraine C" first="Célia" last="Touraine">Célia Touraine</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Anota, Amelie" sort="Anota, Amelie" uniqKey="Anota A" first="Amélie" last="Anota">Amélie Anota</name>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:32809099</idno>
<idno type="pmid">32809099</idno>
<idno type="doi">10.1007/s11136-020-02605-3</idno>
<idno type="wicri:Area/Main/Corpus">000099</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000099</idno>
<idno type="wicri:Area/Main/Curation">000099</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000099</idno>
<idno type="wicri:Area/Main/Exploration">000099</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.</title>
<author>
<name sortKey="Bascoul Mollevi, Caroline" sort="Bascoul Mollevi, Caroline" uniqKey="Bascoul Mollevi C" first="Caroline" last="Bascoul-Mollevi">Caroline Bascoul-Mollevi</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Barbieri, Antoine" sort="Barbieri, Antoine" uniqKey="Barbieri A" first="Antoine" last="Barbieri">Antoine Barbieri</name>
<affiliation wicri:level="3">
<nlm:affiliation>Inserm UMR 1219, University Bordeaux, Bordeaux, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Inserm UMR 1219, University Bordeaux, Bordeaux</wicri:regionArea>
<placeName>
<region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Bourgier, Celine" sort="Bourgier, Celine" uniqKey="Bourgier C" first="Céline" last="Bourgier">Céline Bourgier</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Radiation Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Radiation Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Conroy, Thierry" sort="Conroy, Thierry" uniqKey="Conroy T" first="Thierry" last="Conroy">Thierry Conroy</name>
<affiliation wicri:level="3">
<nlm:affiliation>Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Grand Est</region>
<region type="old region" nuts="2">Lorraine (région)</region>
<settlement type="city">Vandœuvre-lès-Nancy</settlement>
<settlement type="city" wicri:auto="agglo">Nancy</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Lorraine University, APEMAC, Team MICS, Nancy, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Lorraine University, APEMAC, Team MICS, Nancy</wicri:regionArea>
<placeName>
<region type="region">Grand Est</region>
<region type="old region">Lorraine (région)</region>
<settlement type="city">Nancy</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Chauffert, Bruno" sort="Chauffert, Bruno" uniqKey="Chauffert B" first="Bruno" last="Chauffert">Bruno Chauffert</name>
<affiliation wicri:level="3">
<nlm:affiliation>Medical Oncology Department, Amiens University Hospital, Amiens, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Medical Oncology Department, Amiens University Hospital, Amiens</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Picardie</region>
<settlement type="city">Amiens</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hebbar, Mohamed" sort="Hebbar, Mohamed" uniqKey="Hebbar M" first="Mohamed" last="Hebbar">Mohamed Hebbar</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Medical Oncology, University Hospital, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, University Hospital, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Jacot, William" sort="Jacot, William" uniqKey="Jacot W" first="William" last="Jacot">William Jacot</name>
<affiliation wicri:level="3">
<nlm:affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Medical Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Juzyna, Beata" sort="Juzyna, Beata" uniqKey="Juzyna B" first="Beata" last="Juzyna">Beata Juzyna</name>
<affiliation wicri:level="3">
<nlm:affiliation>R&D Unicancer, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>R&D Unicancer, Paris</wicri:regionArea>
<placeName>
<region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="De Forges, Helene" sort="De Forges, Helene" uniqKey="De Forges H" first="Hélène" last="De Forges">Hélène De Forges</name>
<affiliation wicri:level="3">
<nlm:affiliation>Clinical Research and Innovation Department, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Research and Innovation Department, Institut du Cancer Montpellier, University Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Gourgou, Sophie" sort="Gourgou, Sophie" uniqKey="Gourgou S" first="Sophie" last="Gourgou">Sophie Gourgou</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Bonnetain, Franck" sort="Bonnetain, Franck" uniqKey="Bonnetain F" first="Franck" last="Bonnetain">Franck Bonnetain</name>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Touraine, Celia" sort="Touraine, Celia" uniqKey="Touraine C" first="Célia" last="Touraine">Célia Touraine</name>
<affiliation wicri:level="3">
<nlm:affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Anota, Amelie" sort="Anota, Amelie" uniqKey="Anota A" first="Amélie" last="Anota">Amélie Anota</name>
<affiliation wicri:level="3">
<nlm:affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>National Platform Quality of Life and Cancer, Montpellier</wicri:regionArea>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Languedoc-Roussillon</region>
<settlement type="city">Montpellier</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<nlm:affiliation>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon</wicri:regionArea>
<placeName>
<region type="region">Bourgogne-Franche-Comté</region>
<region type="old region">Franche-Comté</region>
<settlement type="city">Besançon</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</title>
<idno type="eISSN">1573-2649</idno>
<imprint>
<date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Longitudinal Studies (MeSH)</term>
<term>Male (MeSH)</term>
<term>Neoplasms (psychology)</term>
<term>Neoplasms (therapy)</term>
<term>Quality of Life (psychology)</term>
<term>Surveys and Questionnaires (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Enquêtes et questionnaires (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Qualité de vie (psychologie)</term>
<term>Tumeurs (psychologie)</term>
<term>Tumeurs (thérapie)</term>
<term>Études longitudinales (MeSH)</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr">
<term>Qualité de vie</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en">
<term>Neoplasms</term>
<term>Quality of Life</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Female</term>
<term>Humans</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Surveys and Questionnaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Enquêtes et questionnaires</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Études longitudinales</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>PURPOSE</b>
</p>
<p>Health-related quality of life (HRQoL) is assessed by self-administered questionnaires throughout the care process. Classically, two longitudinal statistical approaches were mainly used to study HRQoL: linear mixed models (LMM) or time-to-event models for time to deterioration/time until definitive deterioration (TTD/TUDD). Recently, an alternative strategy based on generalized linear mixed models for categorical data has also been proposed: the longitudinal partial credit model (LPCM). The objective of this article is to evaluate these methods and to propose recommendations to standardize longitudinal analysis of HRQoL data in cancer clinical trials.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>METHODS</b>
</p>
<p>The three methods are first described and compared through statistical, methodological, and practical arguments, then applied on real HRQoL data from clinical cancer trials or published prospective databases. In total, seven French studies from a collaborating group were selected with longitudinal collection of QLQ-C30. Longitudinal analyses were performed with the three approaches using SAS, Stata and R software.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>RESULTS</b>
</p>
<p>We observed concordant results between LMM and LPCM. However, discordant results were observed when we considered the TTD/TUDD approach compared to the two previous methods. According to methodological and practical arguments discussed, the approaches seem to provide additional information and complementary interpretations. LMM and LPCM are the most powerful methods on simulated data, while the TTD/TUDD approach gives more clinically understandable results. Finally, for single-item scales, LPCM is more appropriate.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>CONCLUSION</b>
</p>
<p>These results pledge for the recommendation to use of both the LMM and TTD/TUDD longitudinal methods, except for single-item scales, establishing them as the consensual methods for publications reporting HRQoL.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">32809099</PMID>
<DateCompleted>
<Year>2021</Year>
<Month>03</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised>
<Year>2021</Year>
<Month>03</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-2649</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2021</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</Title>
<ISOAbbreviation>Qual Life Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.</ArticleTitle>
<Pagination>
<MedlinePgn>91-103</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11136-020-02605-3</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Health-related quality of life (HRQoL) is assessed by self-administered questionnaires throughout the care process. Classically, two longitudinal statistical approaches were mainly used to study HRQoL: linear mixed models (LMM) or time-to-event models for time to deterioration/time until definitive deterioration (TTD/TUDD). Recently, an alternative strategy based on generalized linear mixed models for categorical data has also been proposed: the longitudinal partial credit model (LPCM). The objective of this article is to evaluate these methods and to propose recommendations to standardize longitudinal analysis of HRQoL data in cancer clinical trials.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The three methods are first described and compared through statistical, methodological, and practical arguments, then applied on real HRQoL data from clinical cancer trials or published prospective databases. In total, seven French studies from a collaborating group were selected with longitudinal collection of QLQ-C30. Longitudinal analyses were performed with the three approaches using SAS, Stata and R software.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed concordant results between LMM and LPCM. However, discordant results were observed when we considered the TTD/TUDD approach compared to the two previous methods. According to methodological and practical arguments discussed, the approaches seem to provide additional information and complementary interpretations. LMM and LPCM are the most powerful methods on simulated data, while the TTD/TUDD approach gives more clinically understandable results. Finally, for single-item scales, LPCM is more appropriate.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results pledge for the recommendation to use of both the LMM and TTD/TUDD longitudinal methods, except for single-item scales, establishing them as the consensual methods for publications reporting HRQoL.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Bascoul-Mollevi</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-4827-3684</Identifier>
<AffiliationInfo>
<Affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>National Platform Quality of Life and Cancer, Montpellier, France. Caroline.Mollevi@icm.unicancer.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Barbieri</LastName>
<ForeName>Antoine</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Inserm UMR 1219, University Bordeaux, Bordeaux, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bourgier</LastName>
<ForeName>Céline</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Radiation Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Conroy</LastName>
<ForeName>Thierry</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Lorraine University, APEMAC, Team MICS, Nancy, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Chauffert</LastName>
<ForeName>Bruno</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Medical Oncology Department, Amiens University Hospital, Amiens, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hebbar</LastName>
<ForeName>Mohamed</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, University Hospital, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jacot</LastName>
<ForeName>William</ForeName>
<Initials>W</Initials>
<AffiliationInfo>
<Affiliation>Institut de Recherche en Cancérologie de Montpellier Inserm U1194, University Montpellier, 208 rue des Apothicaire, Montpellier Cedex 5, 34298, Montpellier, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Department of Medical Oncology, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Juzyna</LastName>
<ForeName>Beata</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>R&D Unicancer, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>De Forges</LastName>
<ForeName>Hélène</ForeName>
<Initials>H</Initials>
<AffiliationInfo>
<Affiliation>Clinical Research and Innovation Department, Institut du Cancer Montpellier, University Montpellier, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gourgou</LastName>
<ForeName>Sophie</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bonnetain</LastName>
<ForeName>Franck</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Touraine</LastName>
<ForeName>Célia</ForeName>
<Initials>C</Initials>
<AffiliationInfo>
<Affiliation>Biometrics Unit - CTD INCa, Institut du Cancer Montpellier, Univ. Montpellier, Montpellier, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Anota</LastName>
<ForeName>Amélie</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>National Platform Quality of Life and Cancer, Montpellier, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, Bourgogne Franche-Comté University, Inserm, EFS BFC, Fédération Hospitalo-Universitaire INCREASE, Besançon, France.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>Grant INCa_Inserm_DGOS_12553</GrantID>
<Agency>SIRIC</Agency>
<Country></Country>
</Grant>
<Grant>
<GrantID>AAR2013-01</GrantID>
<Agency>IReSP</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2020</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Qual Life Res</MedlineTA>
<NlmUniqueID>9210257</NlmUniqueID>
<ISSNLinking>0962-9343</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Cancer</Keyword>
<Keyword MajorTopicYN="N">Clinical trial</Keyword>
<Keyword MajorTopicYN="N">Generalized linear mixed model</Keyword>
<Keyword MajorTopicYN="N">Health-related quality of life</Keyword>
<Keyword MajorTopicYN="N">Longitudinal analysis</Keyword>
<Keyword MajorTopicYN="N">Time to deterioration</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="accepted">
<Year>2020</Year>
<Month>08</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2020</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2021</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2020</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">32809099</ArticleId>
<ArticleId IdType="doi">10.1007/s11136-020-02605-3</ArticleId>
<ArticleId IdType="pii">10.1007/s11136-020-02605-3</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Osoba, D. (2011). Health-related quality of life and cancer clinical trials. Therapeutic Advances in Medical Oncology, 3(2), 57–71.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1177/1758834010395342</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The european organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of National Cancer Institute, 85(5), 365–376.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1093/jnci/85.5.365</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Fayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. on behalf of the E. Q. of L. Group. (2001). EORTC QLQ-C30 Scoring Manual (3rd edition).</Citation>
</Reference>
<Reference>
<Citation>Bonnetain, F., Fiteni, F., Efficace, F., & Anota, A. (2016). Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology, 34(16), 1953–1956.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1200/JCO.2014.56.7974</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Kiebert, G. M., Curran, D., & Aaronson, N. K. (1998). Quality of life as an endpoint in EORTC clinical trials european organization for research and treatment for cancer. Statistics in Medicine, 17(57), 561–569.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1002/(SICI)1097-0258(19980315/15)17:5/7<561::AID-SIM803>3.0.CO;2-S</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hamel, J.-F., Saulnier, P., Pe, M., Zikos, E., Musoro, J., Coens, C., et al. (2017). A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials. European Journal of Cancer, 83, 166–176.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1016/j.ejca.2017.06.025</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., et al. (2014). Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 709–722.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1056/NEJMoa1308345</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., et al. (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 699–708.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1056/NEJMoa1308573</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Fairclough, D. L. (2002). Design and Analysis of Quality of Life Studies in Clinical Trials. (Boca Raton: Chapman and Hall, Ed.).</Citation>
</Reference>
<Reference>
<Citation>Anota, A., Hamidou, Z., Paget-Bailly, S., Chibaudel, B., Bascoul-Mollevi, C., Auquier, P., et al. (2015). Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: Do we need RECIST for quality of life to achieve standardization? Quality of Life Research, 24(1), 5–18.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1007/s11136-013-0583-6</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Barbieri, A., Peyhardi, J., Conroy, T., Gourgou, S., Lavergne, C., Mollevi, C. (2017). Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials. BMC Medical Research Methodology, 17(1).</Citation>
</Reference>
<Reference>
<Citation>Barbieri, A., Anota, A., Conroy, T., Gourgou-Bourgade, S., Juzyna, B., Bonnetain, F., et al. (2016). Applying the longitudinal model from item response theory to assess health-related quality of life in the PRODIGE 4/ACCORD 11 randomized trial. Medical Decision Making, 36(5), 615–628.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1177/0272989X15621883</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anota, A., Barbieri, A., Savina, M., Pam, A., Gourgou-Bourgade, S., Bonnetain, F., et al. (2014). Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study. Health and Quality of Life Outcomes, 12(1), 1326.</Citation>
</Reference>
<Reference>
<Citation>Charton, E., Cuer, B., Cottone, F., Efficace, F., Touraine, C., Hamidou, Z., et al. (2020). Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review. Quality of Life Research, 29(4), 867–878.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1007/s11136-019-02367-7</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Van der Linden, W. J., Hambleton, R. K. (1997). Handbook of Modern Item Response Theory (Vol. Springer Verlag, New York).</Citation>
</Reference>
<Reference>
<Citation>Bascoul-Mollevi Caroline, Castan Florence, Azria David, Gourgou-Bourgade Sophie. (2015). EORTC QLQ-C30 descriptive analysis with the qlqc30 command. The Stata Journal, pp. 1060–1074. ( https://www.stata-journal.com/article.html?article=dm0084 ).</Citation>
</Reference>
<Reference>
<Citation>Bascoul-Mollevi, C., Savina, M., Anota, A., Barbieri, A., Azria, D., Bonnetain, F., et al. (2018). Longitudinal health-related quality of life analysis in oncology with time to event approaches, the STATA command qlqc30_TTD. Computer Methods and Programs in Biomedicine, 158, 153–159.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1016/j.cmpb.2018.02.010</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anota, A., Savina, M., Bascoul-Mollevi, C., Bonnetain, F. (2017). QoLR: An R package for the longitudinal analysis of health-related quality of life in oncology. Journal of Statistical Software, p. Vol 77: Issue 12. ( https://www.jstatsoft.org/article/view/v077i12 ).</Citation>
</Reference>
<Reference>
<Citation>Troxel, A. B., Fairclough, D. L., Curran, D., & Hahn, E. A. (1998). Statistical analysis of quality of life with missing data in cancer clinical trials. Statistics in Medicine, 17(5–7), 653–666.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1002/(SICI)1097-0258(19980315/15)17:5/7<653::AID-SIM812>3.0.CO;2-M</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., del Campo, J. M., et al. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): Results from a double-blind, phase 3, randomised controlled trial. The Lancet Oncology, 19(8), 1117–1125.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1016/S1470-2045(18)30333-4</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Azria, D., Belkacemi, Y., Romieu, G., Gourgou, S., Gutowski, M., Zaman, K., et al. (2010). Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. The lancet oncology, 11(3), 258–265.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1016/S1470-2045(10)70013-9</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carayol, M., Romieu, G., Bleuse, J. P., Senesse, P., Gourgou-Bourgade, S., Sari, C., et al. (2013). Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: Design and implementation of a prospective randomized controlled trial. Contemporary Clinical Trials, 36, 531–543.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1016/j.cct.2013.09.016</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Carayol, M., Ninot, G., Senesse, P., Bleuse, J.-P., Gourgou, S., Sancho-Garnier, H., et al. (2019). Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: The “APAD1” randomized controlled trial. BMC cancer, 19(1), 737.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1186/s12885-019-5896-6</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Dabakuyo, T. S., Guillemin, F., Conroy, T., Velten, M., Jolly, D., Mercier, M., et al. (2013). Response shift effects on measuring post-operative quality of life among breast cancer patients: A multicenter cohort study. Quality of life research, 22(1), 1–11.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1007/s11136-012-0135-5</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hebbar, M., Chibaudel, B., Andre, T., Mineur, L., Smith, D., Louvet, C., et al. (2015). FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): A pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Annals of Oncology, 26, 1040.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1093/annonc/mdv141</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Conroy, T., Galais, M.-P., Raoul, J.-L., Bouché, O., Gourgou-Bourgade, S., Douillard, J.-Y., et al. (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. The lancet oncology, 15(3), 305–314.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1016/S1470-2045(14)70028-2</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine, 364(19), 1817–1825.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1056/NEJMoa1011923</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Frappaz, D., Taillia, H., et al. (2014). Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: Final results of the TEMAVIR study from ANOCEF†. Annals of Oncology, 25(7), 1442–1447.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1093/annonc/mdu148</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Musoro, Z. J., Hamel, J.-F., Ediebah, D. E., Cocks, K., King, M. T., Groenvold, M., et al. (2018). Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol. British Medical Journal Open, 8(1), e019117.</Citation>
</Reference>
<Reference>
<Citation>Taphoorn, M. J. B., Henriksson, R., Bottomley, A., Cloughesy, T., Wick, W., Mason, W. P., et al. (2015). Health-related quality of life in a randomized phase iii study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. Journal of Clinical Oncology, 33(19), 2166–2175.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1200/JCO.2014.60.3217</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Calvert, M., Blazeby, J., Altman, D. G., Revicki, D. A., Moher, D., Brundage, M. D., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA, 309(8), 814–822.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1001/jama.2013.879</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bottomley, A., Pe, M., Sloan, J., Basch, E., Bonnetain, F., Calvert, M., et al. (2016). Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. The Lancet. Oncology, 17(11), e510–e514.</Citation>
<ArticleIdList>
<ArticleId IdType="doi">10.1016/S1470-2045(16)30510-1</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Bottomley, A., Pe, M., Sloan, J., Basch, E., Bonnetain, F., Calvert, M., Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) Consortium. (2018). Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clinical Trials, 1740774518795637.</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Aquitaine</li>
<li>Bourgogne-Franche-Comté</li>
<li>Franche-Comté</li>
<li>Grand Est</li>
<li>Hauts-de-France</li>
<li>Languedoc-Roussillon</li>
<li>Lorraine (région)</li>
<li>Nord-Pas-de-Calais</li>
<li>Nouvelle-Aquitaine</li>
<li>Occitanie (région administrative)</li>
<li>Picardie</li>
<li>Île-de-France</li>
</region>
<settlement>
<li>Amiens</li>
<li>Besançon</li>
<li>Bordeaux</li>
<li>Lille</li>
<li>Montpellier</li>
<li>Nancy</li>
<li>Paris</li>
<li>Vandœuvre-lès-Nancy</li>
</settlement>
</list>
<tree>
<country name="France">
<region name="Occitanie (région administrative)">
<name sortKey="Bascoul Mollevi, Caroline" sort="Bascoul Mollevi, Caroline" uniqKey="Bascoul Mollevi C" first="Caroline" last="Bascoul-Mollevi">Caroline Bascoul-Mollevi</name>
</region>
<name sortKey="Anota, Amelie" sort="Anota, Amelie" uniqKey="Anota A" first="Amélie" last="Anota">Amélie Anota</name>
<name sortKey="Anota, Amelie" sort="Anota, Amelie" uniqKey="Anota A" first="Amélie" last="Anota">Amélie Anota</name>
<name sortKey="Anota, Amelie" sort="Anota, Amelie" uniqKey="Anota A" first="Amélie" last="Anota">Amélie Anota</name>
<name sortKey="Barbieri, Antoine" sort="Barbieri, Antoine" uniqKey="Barbieri A" first="Antoine" last="Barbieri">Antoine Barbieri</name>
<name sortKey="Bascoul Mollevi, Caroline" sort="Bascoul Mollevi, Caroline" uniqKey="Bascoul Mollevi C" first="Caroline" last="Bascoul-Mollevi">Caroline Bascoul-Mollevi</name>
<name sortKey="Bascoul Mollevi, Caroline" sort="Bascoul Mollevi, Caroline" uniqKey="Bascoul Mollevi C" first="Caroline" last="Bascoul-Mollevi">Caroline Bascoul-Mollevi</name>
<name sortKey="Bonnetain, Franck" sort="Bonnetain, Franck" uniqKey="Bonnetain F" first="Franck" last="Bonnetain">Franck Bonnetain</name>
<name sortKey="Bonnetain, Franck" sort="Bonnetain, Franck" uniqKey="Bonnetain F" first="Franck" last="Bonnetain">Franck Bonnetain</name>
<name sortKey="Bonnetain, Franck" sort="Bonnetain, Franck" uniqKey="Bonnetain F" first="Franck" last="Bonnetain">Franck Bonnetain</name>
<name sortKey="Bourgier, Celine" sort="Bourgier, Celine" uniqKey="Bourgier C" first="Céline" last="Bourgier">Céline Bourgier</name>
<name sortKey="Bourgier, Celine" sort="Bourgier, Celine" uniqKey="Bourgier C" first="Céline" last="Bourgier">Céline Bourgier</name>
<name sortKey="Chauffert, Bruno" sort="Chauffert, Bruno" uniqKey="Chauffert B" first="Bruno" last="Chauffert">Bruno Chauffert</name>
<name sortKey="Conroy, Thierry" sort="Conroy, Thierry" uniqKey="Conroy T" first="Thierry" last="Conroy">Thierry Conroy</name>
<name sortKey="Conroy, Thierry" sort="Conroy, Thierry" uniqKey="Conroy T" first="Thierry" last="Conroy">Thierry Conroy</name>
<name sortKey="De Forges, Helene" sort="De Forges, Helene" uniqKey="De Forges H" first="Hélène" last="De Forges">Hélène De Forges</name>
<name sortKey="Gourgou, Sophie" sort="Gourgou, Sophie" uniqKey="Gourgou S" first="Sophie" last="Gourgou">Sophie Gourgou</name>
<name sortKey="Gourgou, Sophie" sort="Gourgou, Sophie" uniqKey="Gourgou S" first="Sophie" last="Gourgou">Sophie Gourgou</name>
<name sortKey="Hebbar, Mohamed" sort="Hebbar, Mohamed" uniqKey="Hebbar M" first="Mohamed" last="Hebbar">Mohamed Hebbar</name>
<name sortKey="Jacot, William" sort="Jacot, William" uniqKey="Jacot W" first="William" last="Jacot">William Jacot</name>
<name sortKey="Jacot, William" sort="Jacot, William" uniqKey="Jacot W" first="William" last="Jacot">William Jacot</name>
<name sortKey="Juzyna, Beata" sort="Juzyna, Beata" uniqKey="Juzyna B" first="Beata" last="Juzyna">Beata Juzyna</name>
<name sortKey="Touraine, Celia" sort="Touraine, Celia" uniqKey="Touraine C" first="Célia" last="Touraine">Célia Touraine</name>
<name sortKey="Touraine, Celia" sort="Touraine, Celia" uniqKey="Touraine C" first="Célia" last="Touraine">Célia Touraine</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000015 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000015 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    AutomedicationFrancoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32809099
   |texte=   Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32809099" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AutomedicationFrancoV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 15 15:24:36 2021. Site generation: Mon Mar 15 15:32:03 2021